3T Biosciences develops transformative T-cell receptor (TCR) therapeutics aimed at treating solid tumors and immune-mediated diseases in diverse patient populations. The company addresses the limitations of current immunotherapies by enhancing the specificity and efficacy of T-cell responses against cancer cells.
Funding
$52M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
WVFounders
Product
Problem
Current cancer immunotherapies often struggle to effectively target solid tumors and immune-mediated diseases across diverse patient populations. Existing treatments may lack the specificity needed to differentiate between healthy and cancerous cells, leading to off-target effects and limited efficacy.
Solution
3T Biosciences is developing T-cell receptor (TCR) therapeutics designed to overcome the limitations of existing immunotherapies. The company focuses on enhancing the specificity and efficacy of T-cell responses against cancer cells, aiming to provide transformative treatments for solid tumors and immune-mediated diseases. By improving the precision of T-cell targeting, 3T Biosciences seeks to broaden the applicability of immunotherapy to a wider range of patients.
Target Audience
The primary target audience includes patients with solid tumors and immune-mediated diseases, as well as healthcare providers seeking more effective immunotherapy options.
Features
- Development of next-generation TCR therapeutics
- Focus on solid tumors and immune-mediated diseases
- Enhancement of T-cell specificity and efficacy